| Literature DB >> 28486417 |
Rachel Carroll1, Andrew B Lawson2, Christel Faes3, Russell S Kirby4, Mehreteab Aregay5, Kevin Watjou6.
Abstract
Oral cavity and pharynx cancer, even when considered together, is a fairly rare disease. Implementation of multivariate modeling with lung and bronchus cancer, as well as melanoma cancer of the skin, could lead to better inference for oral cavity and pharynx cancer. The multivariate structure of these models is accomplished via the use of shared random effects, as well as other multivariate prior distributions. The results in this paper indicate that care should be taken when executing these types of models, and that multivariate mixture models may not always be the ideal option, depending on the data of interest.Entities:
Keywords: disease mapping; incidence; lung and bronchus cancer; melanoma cancer of the skin; mixture model; oral cavity and pharynx cancer; spatio-temporal
Mesh:
Year: 2017 PMID: 28486417 PMCID: PMC5451954 DOI: 10.3390/ijerph14050503
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Number and percent of zeros and imputed data per threshold.
| 0 | 1–4 | 5–10 | |
|---|---|---|---|
| 16 (2.5%) | 200 (31.1%) | 190 (29.5%) | |
| 13 (2.0%) | 128 (19.9%) | 151 (23.4%) | |
| 0 (0.0%) | 4 (0.6%) | 15 (2.3%) | |
Figure 1Bar plot of incidences of all cancers over time.
Figure 2SIR of oral cavity and pharynx cancer.
Figure 3SIR of melanoma cancer of the skin.
Figure 4SIR of lung and bronchus cancer.
Alternative mixture term definitions.
| Model | Spatial | Temporal | Spatio-Temporal | Mixture Parameter |
|---|---|---|---|---|
| Univariate | ||||
| F2PRED | - | |||
| Alt1 | - | |||
| Alt2 | ||||
| Bivariate/Multivariate 1 | ||||
| F2PRED | - | |||
| Alt1 | - | |||
| Alt2 | ||||
| Alt3a | - | |||
| Alt3b | - | |||
1 Note that bivariate and multivariate expressions can be grouped together because the only difference in their structure is that for the former and for the latter.
Goodness of fit results for oral cavity and pharynx cancer.1
| F2PRED | Alt1 | Alt2 | Alt1 | Alt2 | Alt3a | Alt3b | F2PRED | Alt1 | Alt2 | Alt3a | Alt3b | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ’96–‘09 | 3241.74 | 3239.09 | 4448.71 | 3196.02 | 3194.97 | 3431.50 | 3426.94 | 3520.64 | 3470.28 | 4184.67 | |||
| ’96–‘05 | 2298.34 | 2296.40 | 3130.11 | 2285.45 | 2479.40 | 2322.88 | 2473.00 | 2954.48 | |||||
| ’06–‘09 | 943.40 | 942.69 | 1318.60 | 930.73 | 930.40 | 1146.05 | 1000.37 | 1197.76 | 997.28 | 1230.20 | |||
| ’96–‘09 | 105.89 | 105.29 | 157.31 | 94.31 | 96.66 | 93.44 | 93.76 | 131.08 | 131.07 | 141.69 | 149.43 | 501.02 | |
| ’96–‘05 | 75.39 | 74.35 | 96.14 | 65.53 | 68.85 | 66.34 | 65.84 | 74.29 | 103.97 | 73.92 | 106.24 | 344.19 | |
| ’06–‘09 | 30.50 | 30.94 | 61.17 | 28.79 | 27.80 | 27.09 | 27.92 | 56.78 | 42.40 | 67.78 | 43.18 | 156.83 | |
| ’96–‘09 | 153.44 | 154.03 | 117.00 | 117.93 | 116.81 | 115.23 | 14,050.59 | 14,037.08 | 13,995.61 | 13,953.98 | 13,678.78 | ||
| ’96–‘05 | 103.93 | 103.75 | 84.43 | 84.53 | 80.58 | 82.13 | 82.00 | 73.51 | 79.94 | 74.44 | 73.05 | ||
| ’06–‘09 | 49.51 | 50.28 | 32.57 | 33.40 | 34.68 | 33.22 | 13,977.08 | 13,965.29 | 13,915.67 | 13,879.53 | 13,605.73 | ||
1 Values in bold indicate the model with superior fit for that measure and time period. If multiple measures are indicated as superior for the same measure and time period combination, they are statistically equivalent. 2 The bivariate and multivariate results are the goodness of fit estimates related specifically to oral/pharynx. Even though multiple diseases were fit, these measures can be calculated in a way such that they only pertain to the fit of the individual diseases.
Figure 5Overall posterior mean risk estimate ( for lung and bronchus cancers, as well as oral cavity and pharynx cancer from model Alt2B for a selection of years.